Search Results
May 20, 2026, 11:48 ET Abra Reports First Quarter 2026 Performance
OperatingATR723
More news about: Abra Group
May 19, 2026, 06:31 ET Netherton Syndrome Market Set to Expand During the Forecast Period (2026-2036) as Novel Therapies Enter Development Pipeline | DelveInsight
August 2025, Azitra announced that topline data from the Phase Ib trial of ATR-12 in patients with Netherton syndrome are expected in the first quarter of 2026. This update highlights the continued clinical progress of ATR-12 as an emerging therapeutic candidate in this rare genetic dermatological disorder.In
More news about: DelveInsight Business Research, LLP
May 14, 2026, 16:40 ET Atrium Therapeutics Reports First Quarter 2026 Financial Results
Upcoming MilestonesSubmit IND application for ATR 1072 in the second half of 2026Initiate Phase 1/2 clinical trial for ATR 1072, subject to regulatory clearanceFile IND application for ATR 1086 in 2027, with IND-enabling studies initiating in 2026First
More news about: Atrium Therapeutics
May 13, 2026, 16:00 ET CytoSorbents Reports First Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update
achieving operating cash flow breakeven in the second half of this year." DrugSorb-ATR® for Brilinta®"In August 2025, we received the FDA's decision on our appeal of the original DrugSorb-ATR application. Importantly, the Agency identified no concerns regarding device safety but
More news about: Cytosorbents Corp
May 13, 2026, 08:30 ET Azitra, Inc. Announces Q1 2026 Results and Provides Business Updates
EGFRi associated rash, which impacts approximately 150,000 people in the U.S. Azitra has an open IND for its ATR-04 program in patients with EGFRi associated rash. The ATR-12 and ATR-04 programs were developed from Azitra's proprietary platform of engineered proteins and topical live biotherapeutic products
More news about: Azitra, Inc.
May 12, 2026, 08:03 ET Latent AI Demonstrates New Physical AI Terminal Homing Capability
Built on the company's Field Tactical Suite (FTS), the new autonomous capability under development integrates Automated Target Recognition (ATR) with flight control on embedded hardware, enabling a one-click strike capability. This will allow a drone to autonomously track and follow an operator-designated
More news about: Latent AI
May 06, 2026, 08:00 ET Azitra, Inc. Announces New U.S. Patent Protecting ATR-12 Program
for EGFRi associated rash, which impacts approximately 150,000 people in the U.S. Azitra has an open IND for its ATR-04 program in patients with EGFRi associated rash. The ATR-12 and ATR-04 programs were developed from Azitra's proprietary platform of engineered proteins and topical live biotherapeutic
More news about: Azitra, Inc.
Apr 30, 2026, 07:00 ET CytoSorbents to Report First Quarter 2026 Financial Results and Recent Business Highlights
cardiothoracic surgery. The Company is actively pursuing regulatory approval of DrugSorb®-ATR with the U.S. FDA and will pursue regulatory approval with Health Canada with better visibility from the FDA. DrugSorb®-ATR is not yet granted or approved in either the U.S. or Canada.The Company has numerous
More news about: Cytosorbents Corp
Apr 28, 2026, 08:02 ET Azitra, Inc. Announces Poster Presentation at ASGCT 2026 Highlighting ATR-01 Program for Ichthyosis Vulgaris
for EGFRi associated rash, which impacts approximately 150,000 people in the U.S. Azitra has an open IND for its ATR-04 program in patients with EGFRi associated rash. The ATR-12 and ATR-04 programs were developed from Azitra's proprietary platform of engineered proteins and topical live biotherapeutic
More news about: Azitra, Inc.
Apr 23, 2026, 08:00 ET Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration
non-specific tissue delivery. The Company's pipeline consists of two precision cardiology candidates, ATR 1072 for PRKAG2 (Protein Kinase AMP-activated non-catalytic subunit Gamma 2) syndrome and ATR 1086 for PLN (phospholamban) cardiomyopathy, and two undisclosed research targets in rare cardiomyopathies.For
More news about: Atrium Therapeutics
Apr 20, 2026, 22:46 ET Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
heart overcoming challenges associated with non-specific tissue delivery. The Company's pipeline consists of two precision cardiology candidates, ATR 1072 and ATR 1086, and two undisclosed research targets in rare cardiomyopathies. For more information about our RNA delivery platform, development pipeline
More news about: Atrium Therapeutics
Apr 17, 2026, 07:00 ET RTX's Pratt & Whitney Canada launches PT6C-67C and PW127XT MRO services in Singapore
PT6C-67C-powered Leonardo AW139 helicopters operating in the region, while increasing global MRO capacity for the PW127XT engine which powers current generation ATR 42/72 aircraft, with future application on the Deutsche Aircraft D328eco. Pratt & Whitney is an RTX (NYSE: RTX) business. "Pratt & Whitney
More news about: RTX
Apr 15, 2026, 10:43 ET CAE and InterGlobe inaugurate new pilot training centre in Mumbai to support India's aviation growth
simulators, with plans to scale to 23 in the coming years. The Mumbai centre will support comprehensive pilot training services, complemented by Airbus, ATR, and Boeing training delivered across the CSTPL network in India, including type rating, recurrent training, and proficiency checks.This growth
More news about: CAE Inc.
Apr 08, 2026, 09:00 ET Avalara to Deliver Fully Embedded, Automated Sales Tax Compliance Tool to Small Businesses Within the Clover Platform
run their business."Avalara's goal is to make tax compliance as seamless and invisible as possible for merchants," said Evan Wright, GM of ATR, AI Content Solutions, and DAVO by Avalara. "By embedding our technology directly into Clover, we're helping businesses more easily manage complex
More news about: Avalara, Inc.
Mar 25, 2026, 16:05 ET CytoSorbents Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
while providing clinicians a valuable therapy to improve patient outcomes.C. DrugSorb®-ATR Regulatory UpdateIn 2025, we made significant strides towards advancing DrugSorb-ATR - a two-time U.S. Food and Drug Administration (FDA) Breakthrough Device - through the FDA De Novo
More news about: Cytosorbents Corp
Mar 19, 2026, 13:13 ET Azitra Announces Pricing of Private Placement Financing of up to Approximately $10.5 Million with up to an Additional Approximately $20.9 Million
for EGFRi associated rash, which impacts approximately 150,000 people in the U.S. Azitra has an open IND for its ATR-04 program in patients with EGFRi associated rash. The ATR-12 and ATR-04 programs were developed from Azitra's proprietary platform of engineered proteins and topical live biotherapeutic
More news about: Azitra, Inc.
Mar 19, 2026, 09:44 ET CytoSorbents Announces HotSwap™ Launch, Renewed Aferetica Partnership, and New Clinical Evidence at ISICEM 2026
cardiothoracic surgery. The Company is actively pursuing regulatory approval of DrugSorb®-ATR with the U.S. FDA and will pursue regulatory approval with Health Canada with better visibility from the FDA. DrugSorb®-ATR is not yet granted or approved in either the U.S. or Canada.The
More news about: Cytosorbents Corp
Mar 18, 2026, 04:30 ET Atrogi announces first subjects dosed in human trial for lead candidate ATR-258
signaling in human skeletal muscle, in overweight male volunteers, who will receive daily oral dosing of ATR-258, Atrogi's GRK-selective long-acting β2-agonist. The study aims to measure the extent to which ATR-258 recapitulates the muscle physiological effects of classic β2 agonists, as well as its potential
More news about: Atrogi AB
Mar 13, 2026, 17:15 ET Azitra Receives Notice of Non-Compliance from NYSE American and Makes NYSE American Section 610(b) Public Announcement
for EGFRi associated rash, which impacts approximately 150,000 people in the U.S. Azitra has an open IND for its ATR-04 program in patients with EGFRi associated rash. The ATR-12 and ATR-04 programs were developed from Azitra's proprietary platform of engineered proteins and topical live biotherapeutic
More news about: Azitra, Inc.
Mar 05, 2026, 16:30 ET Azitra, Inc. Announces Cancellation of 2026 Special Meeting of Stockholders
for EGFRi associated rash, which impacts approximately 150,000 people in the U.S. Azitra has an open IND for its ATR-04 program in patients with EGFRi associated rash. The ATR-12 and ATR-04 programs were developed from Azitra's proprietary platform of engineered proteins and topical live biotherapeutic
More news about: Azitra, Inc.
Mar 05, 2026, 07:00 ET CytoSorbents to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
cardiothoracic surgery. The Company is actively pursuing regulatory approval of DrugSorb®-ATR with the U.S. FDA and will pursue regulatory approval with Health Canada with better visibility from the FDA. DrugSorb®-ATR is not yet granted or approved in either the U.S. or Canada.The Company has numerous
More news about: Cytosorbents Corp
Mar 04, 2026, 10:02 ET Kutta Unveils KED to Transform Edge Computing at the Tactical Edge
aggregation, ATAK/TAK services, video processing, and distributed command and control. Key attributes include:Multi-Stream ATR – Simultaneous Automatic Target Recognition across multiple concurrent video feedsTactical Networking Hub – Aggregates and processes
More news about: Kutta Technologies LLC
Mar 02, 2026, 16:49 ET Shrub Oak International School Announces the Promotion of Deb Brass, MS, ATR-BC, LCAT, to Assistant Director of The Pines at Shrub Oak
March 2, 2026 /PRNewswire/ -- Shrub Oak International School is proud to announce the promotion of Deb Brass, MS, ATR-BC, LCAT, to Assistant Director of The Pines at Shrub Oak, a specialized therapeutic program designed to serve neurodiverse children, adolescents, and
More news about: Shrub Oak International School
Feb 27, 2026, 17:30 ET Azitra, Inc. Announces Full Year 2025 Results and Provides Business Updates
HighlightsInitiated Phase 1/2 Trial for ATR-04 program targeting oncology patients with EGFRi-associated rash; presented ATR-04 trial design and update at ASCO 2025Announced positive preclinical data for ATR-01 program, targeting the treatment of ichthyosis vulgarisReported
More news about: Azitra, Inc.
Feb 27, 2026, 09:19 ET Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies
of Avidity Biosciences advances precision cardiology programs using targeted RNA delivery platform Lead candidates ATR 1072 and ATR 1086 expected to enter clinical trials for PRKAG2 syndrome and PLN cardiomyopathy, respectivelySAN DIEGO,
More news about: Atrium Therapeutics